Tsumura, Dainippon Pharmaceutical to Cease Development of Lercanidipine Hydrochloride, Hypertension Drug Candidate.Tokyo, Japan, Aug 2, 2005 - (JCNN JCNN Japan Corporate News Network ) - Tsumura and Dainippon Pharmaceutical have decided to return their right to develop and sell lercanidipine hydrochloride hydrochloride /hy·dro·chlo·ride/ (-klor´id) a salt of hydrochloric acid. hy·dro·chlo·ride n. A compound resulting from the reaction of hydrochloric acid with an organic base. , a hypertension drug candidate, in Japan to Recordati, an Italian pharmaceutical. The two Japanese companies This is a list of companies from Japan. Note that 株式会社 can be (and frequently is) read both kabushiki kaisha and kabushiki gaisha (with or without a hyphen). See that article for more details. have jointly worked on the development of lercanidipine hydrochloride. However, their latest study indicated that the agent will not be a competitive product in Japan. Consequently, the two companies have announced the decision. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion